- Partner News
- Media Releases
- Mainstream News
Vancouver, British Columbia / October 17, 2022– Agra Ventures Ltd. (“AGRA” or the “Company”) (CSE: AGRA) (OTC: AGFAF), a growth-oriented and diversified company focused on the international cannabis industry, announces its expectation of positive outcomes for the Canadian cannabis industry from Health Canada’s current review (the “Review”) of the Cannabis Act. The purpose of the Review is to assess the effects of the legalization of recreational cannabis on the health outcomes of Canadians. However, the Review is also assessing financial, tax, legal and regulatory matters that could be beneficial to the Canadian cannabis sector. The Review commenced on September 22, 2022 and the Minister of Health must table a report in both Houses of Parliament no later than 18 months after the start of the review.
Companies in the business of licensed cannabis production, including AGRA, are hoping to benefit from the Review as it may lead to improvements in potency and packaging restrictions as well as reductions or the elimination of various tax regulations on cannabis products in Canada. Some of the major challenges faced by companies in the cannabis industry currently include the inability to operate profitably and the difficulty of navigating numerous regulations and restrictions. These difficulties, among others, could be significantly eased as a result of a positive set of changes resulting from the Review.
Below is a list of five key outcomes that AGRA is optimistic will arise from the Review:
The Canadian Federal Government was required by law to conduct a review of the Cannabis Act three years after the legislation was enacted to study the impact of cannabis on public health, young people and indigenous communities. However, the Review is occurring one year later than mandated. AGRA, like many players across the Canadian cannabis industry, is hopeful that a number of changes will result from the Review that will ultimately reduce the purchase and use of illicit cannabis in a significant way.1
“For the sake of our customers, employees, shareholders and other stakeholders, AGRA’s hope is that Health Canada will take this opportunity to accept many of the reasonable recommendations being made by industry to significantly improve the viability of the regulated cannabis industry for the long term,” said Nick Kuzyk, Interim CEO of AGRA.
“Canadian cannabis consumers need the Review to go well because the economic health of many licensed producers, processors, retailers and other members of the industry are currently at risk under the current framework. AGRA is fortunate to have great infrastructure and expertise within its Boundary Bay Cannabis joint venture. But still, it is very challenging to generate operating income in this environment, let alone net profit,” added Mr. Kuzyk.
About AgraFlora Organics International Inc.
Agra Ventures is a growth-oriented and diversified company focused on the international cannabis industry. The company is dedicated to the cultivation, distribution and marketing of high-quality cannabis and cannabis-infused products worldwide. Agra Ventures’ primary asset in Canada is Boundary Bay Cannabis located in Delta, BC, which is one of the largest cannabis greenhouse facilities focused on the cost-optimized cultivation of high-potency cannabis. Abroad, the company’s wholly owned subsidiary, Farmako GmbH, is focused on becoming Europe’s leading distributor of medical cannabis. Farmako currently has active product distribution operations in Germany and is fully licensed in the United Kingdom.
For more information about Agra Ventures, please visit www.agraventures.com and its profile page on SEDAR at www.sedar.com.
ON BEHALF OF THE BOARD OF DIRECTORS
Nick Kuzyk, Interim CEO
T: (800) 783-6056